AI Article Synopsis
- The study looked at multiple myeloma patients who were treated with a specific medicine combination called VRd.
- Out of 1497 patients, 33% got a lighter version of the treatment and 22% got a reduced dose.
- Older patients and females were more likely to get the lighter or reduced treatments, which might make the medicine less effective for some.
Article Abstract
To evaluate among multiple myeloma (MM) patients, the proportions with first-line bortezomib/lenalidomide/dexamethasone (VRd) dose modifications and the associated baseline patient characteristics. Adult MM patients treated with first-line VRd were selected from the Optum claims database. VRd dose modifications were defined based on lenalidomide dose. Among 1497 MM patients, 33% received VRd lite and 22% VRd reduced. Compared with VRd regular, VRd lite usage was more likely to be associated with patients aged ≥75 years and female sex; VRd reduced usage was more likely to be associated with female sex and frailty. A large proportion of MM patients received VRd dose modifications in the real-world, which could potentially result in reduced effectiveness of VRd.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2022-0933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!